



AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A compound represented by the general formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof:



wherein,



R^1 is selected from a group consisting of $-(CH_2)_{0-4}C(R^{1a}, R^{1b})(CH_2)_{0-4}OR^3$, $-(CH_2)_{0-4}C(O)NR^4R^5$, $-(CH_2)_{0-4}C(R^{1a}, R^{1b})NR^4R^5$, and $-(CH_2)_{0-4}C(R^{1a}, R^{1b})(CH_2)_{0-4}S(O)_{0-2}R^6$, and $-(CH_2)_{0-4}C(R^{1a}, R^{1b})(CH_2)_{0-4}SC(O)R^7$;

wherein, R^{1a} , R^{1b} , R^3 , R^4 , R^5 , and R^6 , and R^7 are each independently selected from a group consisting of H, C_{1-6} alkyl and OH;

$R^{1'}$ is selected from a group consisting of hydrogen and C_{1-6} alkyl;


A_1 , A_2 , and A_3 are each independently selected from a group consisting of CH and N a heteroatom;

X and Y are each independently selected from a group consisting of a benzene ring group, a 3-8 membered unsaturated heterocyclic group, an alkenyl group, an alkynyl group and $-\zeta- \equiv N-\zeta-$;

R^2 is $-\zeta-B-C$,

B is ~~absent or~~ represents $-(C_{1-8}alkyl)-$, wherein 0-2 carbon atoms in said $-(C_{1-8}alkyl)-$ are ~~optionally~~ replaced with -O- or $-NR^8-$,

C is selected from a group consisting of ~~C₁₋₆alkyl~~, -OR⁹, -NR⁹R^{9'}, ~~phenyl~~ and




Q is a group selected from a group consisting of NR^c and O;

R⁸, R⁹ and R^{9'} are each independently selected from hydrogen atom, and C₁₋₆alkyl, ~~and C₃₋₆cycloalkyl~~; and

m is [[0,]] 1, 2 or 3.

2. **(Currently Amended)** The compound according to claim 1, a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof:


wherein,




R¹ is ~~selected from a group consisting of -C(R^{1a},R^{1b})OR³ and -C(O)NR⁴R⁵~~, wherein, R^{1a}, R^{1b}, and R³, ~~R⁴ and R⁵~~ are each independently selected from a group consisting of hydrogen atom, methyl and hydroxyl;

R^{1'} is selected from a group consisting of hydrogen and C₁₋₄alkyl;

A₁, A₂, and A₃ are each independently selected from a group consisting of CH and N;

X and Y are each independently selected from a group consisting of a benzene ring group, ~~5-6 membered unsaturated heterocyclic group~~, an alkenyl group, an alkynyl group and ~~-~~;

R² is ~~-~~-B-C,

B is ~~absent or~~ represents -(C₁₋₄alkyl)-,


C is selected from a group consisting of -OR⁹ and -NR⁹R^{9'},

R⁹ and R^{9'} are each independently selected from hydrogen atom, methyl, ethyl, isopropyl; and

m is [[0,]] 1[[,]] or 2.

3. **(Currently Amended)** The compound according to claim 1, a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof:

wherein,




~~R¹ is selected from a group consisting of -C(H,CH₃)OH and -C(O)NHCH₃;~~

R¹ is selected from a group consisting of H, methyl, and ethyl;

A₁, A₂, and A₃ are each independently selected from a group consisting of CH and N;


X and Y are each independently selected from a group consisting of a benzene ring group, a pyrrole ring group, an imidazole ring group, a pyrazole ring group, a 1,2,3-triazole ring group, a 1,2,4-triazole ring group, a tetrazole ring group, a furan ring group, an oxazole ring group, an isoxazole ring group, a 1,2,4-oxadiazole ring group, a pyridine ring group, an alkenyl group, an alkynyl group, and ,



R² is -CH₂OH; and

m is $[[0 \text{ or}]] 1$.

4. **(Currently Amended)** A compound represented by the general formula (III), [(II)], a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof:



wherein,

W represents ~~-(C₀₋₈alkyl optionally substituted by a substituent group)-C(O)-N(R^{1'})-~~
(C₁₋₈alkyl optionally substituted by R¹)-C(O)-N(H)-OH;

R¹ is each independently selected from a group consisting of C₁₋₈alkyl optionally substituted by OH ~~a substituent group, (C₀₋₈alkyl optionally substituted by a substituent group)C(O)NR⁴R⁵, and~~ -(C₀₋₈alkyl optionally substituted by a substituent group)S(O)₁₋₂R³, and ~~(C₀₋₈alkyl optionally substituted by a substituent group)S(O)₁₋₂NR⁴R⁵, wherein, R³, R⁴, and R⁵ are each independently~~ is selected from a group consisting of hydrogen atom, ~~halogen atom, and~~ C₁₋₈alkyl optionally substituted by a substituent group, ~~C₂₋₈alkenyl optionally substituted by a substituent group and C₂₋₈alkynyl optionally substituted by a substituent group;~~

R^{1'} is selected from a group consisting of hydrogen atom, hydroxyl, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl, ~~halogen atom, carboxyl, C₁₋₈alkyl optionally substituted by a substituent group, C₂₋₈alkenyl optionally substituted by a substituent group and C₂₋₈alkynyl optionally substituted by a substituent group,~~ or R^{1'} and the carbon atom in the ~~C₀₋₈alkyl optionally substituted by a substituent group~~ in the group W, together with the groups N and C(O), form a [[5-6]] 6-membered unsaturated heterocyclic group;

~~A₁, A₂, A₃ is, A₄, A₅, and A₆ are each independently~~ selected from a group consisting of CR^aR^a and ~~[[.]] NR^c, O, and S;~~

X and Y are each independently selected from a group consisting of benzene ring group ~~a bond, a 5-14 membered heteroaryl group optionally substituted by a substituent group, a 6-14 membered aryl group optionally substituted by a substituent group, -(C=C)-, -(C≡C)-, =N-, -C(O)-NR^c,~~ wherein at least one of X and Y is not simultaneously benzene ring group optionally substituted by a substituent group ~~a bond;~~


the five-membered ring moiety containing P₁, P₂, P₃, and P₄ as shown in general formula (III) is selected from a group consisting of a furan group, a pyrrole group, a pyrazole group, a triazole group and a thiophene group;

~~P₁, P₂, P₃, P₄, and P₅ are each independently selected from a group consisting of CR^aR^a, NR^e, O, and S;~~

m represents 1, 2 or 3; an integer of 0-4;

in each occurrence, R^2 each independently represents ---B---C ;

in each occurrence, B independently represents a bond, or is each independently selected from a group consisting of C_{1-8} alkyl optionally in which at least one carbon atom is replaced with at least one group of $[[S,]]$ O and NR^c and/or optionally substituted by a substituent group, C_{2-8} alkenyl optionally in which at least one carbon atom is replaced with at least one group of S, O and NR^e and/or optionally substituted by a substituent group and C_{2-8} alkynyl optionally in which at least one carbon atom is replaced with at least one group of S, O and NR^e and/or optionally substituted by a substituent group;

in each occurrence, C independently represents hydrogen atom, cyano, mercapto, halogen atom, carboxyl, nitro, C_{1-8} alkyl optionally substituted by a substituent group, C_{1-8} alkyloxy optionally substituted by a substituent group, $-OR^c$, $-NR^cR^c$, or ;

Q is a group selected from a group consisting of NR^c and O;

~~3-12 membered cycloalkyl optionally substituted by a substituent group, 3-12 membered heterocyclyl optionally substituted by a substituent group, 5-14 membered heteroaryl optionally substituted by a substituent group and 6-14 membered aryl optionally substituted by a substituent group;~~

R^a either is absent or in each occurrence are each independently selected from a group consisting of hydrogen atom and, cyano, mercapto, halogen atom, carboxyl, nitro, $-OR^e$, $-NR^eR^e$, $-N(OH)R^e$, $-C(O)R^d$, $-C(O)OR^e$, $-C(O)NR^eR^e$, $-OC(O)NR^eR^e$, $-NR^eC(O)OR^e$, $-NR^eC(O)R^d$, $-S(O)_{1-2}NR^eR^e$, $-S(O)_{1-2}R^d$, $-NR^eS(O)_{1-2}R^d$, $-S(O)_{1-2}OR^e$, C_{1-8} alkyl optionally substituted by a substituent group, $(C_{1-8}$ alkyl optionally substituted by a substituent group) OR^e , $(C_{1-8}$ alkyl optionally substituted by a substituent group) NR^eR^e , C_{1-8} alkyloxy optionally substituted by a substituent group, C_{2-8} alkenyl optionally substituted by a substituent group, C_{2-8} alkynyl optionally substituted by a substituent group, 3-12 membered cycloalkyl optionally substituted by a substituent group, 3-12 membered heterocyclyl optionally substituted by a substituent group, 6-14 membered aryl optionally substituted by a substituent group and 5-14 membered heteroaryl optionally substituted by a substituent group;

R^c either is absent or in each occurrence are each independently selected from a group consisting of hydrogen atom and, ~~halogen atom, carboxyl, $C(O)R^d$, $C(O)OR^b$, $C(O)NR^bR^b$, $S(O)_{1-2}NR^bR^b$, $S(O)_{1-2}R^d$, $S(O)_{1-2}OR^b$, C_{1-8} alkyl optionally substituted by a substituent group, $(C_{1-8}$ alkyl optionally substituted by a substituent group) OR^b , $(C_{1-8}$ alkyl optionally substituted by a substituent group) NR^bR^b , C_{2-8} alkenyl optionally substituted by a substituent group, C_{2-8} alkynyl optionally substituted by a substituent group, 3-12 membered cycloalkyl optionally substituted by a substituent group, 3-12 membered heterocyclyl optionally substituted by a substituent group, 6-14 membered aryl optionally substituted by a substituent group and 5-14 membered heteroaryl optionally substituted by a substituent group; or in case that two R^e -groups are attached to the same atom, two R^e -groups, together with the atom attached thereto, form 3-12 membered heterocycle optionally substituted by a substituent group;~~

R^b , in each occurrence, is each independently selected from a group consisting of ~~hydrogen atom, halogen atom, carboxyl, sulfonic acid group, C_{1-8} alkyl optionally substituted by a substituent group, C_{1-8} alkylsulfonyl optionally substituted by a substituent group, C_{1-8} alkylsulfinyl optionally substituted by a substituent group, 3-12 membered cycloalkyl optionally substituted by a substituent group, 3-12 membered heterocyclyl optionally substituted by a substituent group, 6-14 membered aryl optionally substituted by a substituent group and 5-14 membered heteroaryl optionally substituted by a substituent group; or in case that two R^b -groups are attached to the same atom, two R^b -groups, together with the atom attached thereto, form 3-12 membered heterocycle optionally substituted by a substituent group;~~

R^d , in each occurrence, is each independently selected from a group consisting of ~~hydrogen atom, hydroxyl, mercapto, halogen atom, carboxyl, nitro, amino, C_{1-8} alkylamino optionally substituted by a substituent group, $(C_{1-8}$ alkyl optionally substituted by a substituent group) $_2$ amino, sulfonic acid group, C_{1-8} alkyl optionally substituted by a substituent group, C_{1-8} alkyloxy optionally substituted by a substituent group, C_{1-8} alkylsulfonyl optionally substituted by a substituent group, C_{1-8} alkylsulfinyl optionally substituted by a substituent group, 3-12 membered cycloalkyl optionally substituted by a substituent group, 3-12 membered heterocyclyl optionally substituted by a substituent~~

group, ~~6-14 membered aryl optionally substituted by a substituent group and 5-14 membered heteroaryl optionally substituted by a substituent group;~~

said substituent group in "optionally substituted by a substituent group" is each independently selected from a group consisting of hydroxyl and, ~~mercapto, carboxyl, cyano, nitro, amino, halogen atom, sulfonic acid group, C₁₋₈alkyl, C₁₋₈alkoxyC₁₋₈alkyl, hydroxyC₁₋₈alkyl, aminoC₁₋₈alkyl, carboxyC₁₋₈alkyl, ester group C₁₋₈alkyl, C₁₋₈alkyloxy, hydroxyC₁₋₈alkyloxy, aminoC₁₋₈alkyloxy, carboxyC₁₋₈alkyloxy, C₁₋₈alkylC₁₋₈alkyloxy, C₁₋₈alkoxyC₁₋₈alkyloxy, ester group C₁₋₈alkyloxy, C₁₋₈alkylamino, (C₁₋₈alkyl)₂amino, aminoC₁₋₈alkylamino, (aminoC₁₋₈alkyl)₂amino, C₁₋₈alkyl ester group, aminocarbonyl, C₁₋₈alkylaminocarbonyl, (C₁₋₈alkyl)₂aminocarbonyl, C₁₋₈alkylearbonyl, C₁₋₈alkylearbonyloxy, C₁₋₈alkylearbonylamino, C₁₋₈alkylsulfamido, haloC₁₋₈alkyl, haloC₁₋₈alkyloxy, C₁₋₈alkylsulfonyl, C₁₋₈alkylsulfinyl, C₁₋₈alkylthio, 3-12 membered cycloalkyl, 6-14 membered aryl, 3-12 membered heterocyclyl, 5-14 membered heteroaryl and oxo,~~

 in the five-membered ring and the six-membered ring represents a double bond optionally present in the ring;

provided that:

when R¹ represents the C₁₋₈alkyl substituted by a substituent, and the substituent contains hydroxyl, each carbon atom of the C₁₋₈alkyl carries at least one hydrogen;

~~when R¹ represents the C₁₋₈alkyl substituted by a substituent, and the substituent contains hydroxyl, the five-membered ring does not represent the imidazole ring group;~~

when R¹ represents the C₁₋₈alkyl substituted by a substituent, and the substituent contains amino, C₁₋₈alkylamino or (C₁₋₈alkyl)₂amino, at least one of X and Y represents a benzene ring group ~~6-14 membered aryl group~~ optionally substituted by a substituent group; and


~~when the five-membered ring is the thiophene ring group, m is not 0;~~

when the five-membered ring contains one nitrogen atom, the five-membered ring is bonded to X through a non-nitrogen atom [[;]]

~~when R¹ represents (C₀₋₈alkyl optionally substituted by a substituent group)C(O)NR⁴R⁵, neither X nor Y is a bond, the five-membered ring represents the furan ring group, and m is not 0.~~


5. **(Cancelled).**

6. **(Previously Presented)** The compound according to claim 4, a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof, which compound is a compound represented by the following general formula (IV):




wherein each group is defined as in claim 4.


7. **(Original)** The compound according to claim 4, a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof, which compound is a compound represented by the following general formula (V) or (VI):





wherein each group is defined as in claim 4, Z represents C₁₋₈alkyl optionally substituted by R¹, --- represents a single bond or a double bond.

8. **(Currently Amended)** ~~A~~ [[The]] compound ~~according to claim 1~~, a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof, which compound is selected from a group consisting of the following compounds:









9. **(Previously Presented)** A pharmaceutical composition, comprising the compound according to claim 1, a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof.

10. **(Withdrawn)** A method of treating and/or preventing infectious diseases, comprising administering to the subject the compound according to claim 1, or a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof, or a pharmaceutical composition comprising the compound according to claim 1.

11-12. **(Cancelled)**.

13. **(Previously Presented)** A pharmaceutical composition, comprising the compound according to claim 4, a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof.

14. **(Withdrawn – Currently Amended)** A method of treating and/or preventing infectious diseases, comprising administering to the subject the compound according to claim 4, or a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof, or a pharmaceutical composition comprising the compound according to claim [[1]] 4.

15. **(Withdrawn)** The method according to claim 14, wherein the infectious diseases is caused by Gram-negative bacteria.

16. **(Withdrawn)** The method according to claim 10, wherein the infectious diseases is caused by Gram-negative bacteria.

17. **(New)** A pharmaceutical composition, comprising the compound according to claim 8, a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof.

18. **(New-Withdrawn)** A method of treating and/or preventing infectious diseases, comprising administering to the subject the compound according to claim 8, or a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, or a deuterated analog thereof, or a stereoisomer thereof, or a pharmaceutical composition comprising the compound according to claim 8.

19. **(New-Withdrawn)** The method according to claim 18, wherein the infectious diseases is caused by Gram-negative bacteria.